ME 3738

Drug Profile

ME 3738

Alternative Names: ME3738

Latest Information Update: 26 Apr 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Meiji Seika Kaisha
  • Developer Meiji Seika Pharma
  • Class Hepatoprotectants; Triterpenes
  • Mechanism of Action Interferon beta stimulants; Interleukin 6 stimulants; Suppressor of cytokine signalling protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Hepatitis C

Most Recent Events

  • 20 Apr 2012 Discontinued - Phase-II for Hepatitis C in Japan (PO)
  • 01 Apr 2011 Meiji Seika Kaisha is now called Meiji Seika Pharma
  • 03 Nov 2009 Preclinical pharmacodynamics data presented at the 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2009)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top